27 related articles for article (PubMed ID: 38602846)
1. Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.
Li C; Qiao Y; Jiang X; Liu L; Zheng Y; Qiu Y; Cheng C; Zhou F; Zhou Y; Huang W; Ren X; Wang Y; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2023 Sep; 66(17):12432-12445. PubMed ID: 37605297
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the First-in-class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
bioRxiv; 2024 Feb; ():. PubMed ID: 38464025
[TBL] [Abstract][Full Text] [Related]
3. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.
Park KS; Xiong Y; Yim H; Velez J; Babault N; Kumar P; Liu J; Jin J
J Med Chem; 2022 Aug; 65(15):10506-10522. PubMed ID: 35763668
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
Xiong Y; Li F; Babault N; Dong A; Zeng H; Wu H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
J Med Chem; 2017 Mar; 60(5):1876-1891. PubMed ID: 28135087
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
[TBL] [Abstract][Full Text] [Related]
7. Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Rahman Z; Bazaz MR; Devabattula G; Khan MA; Godugu C
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22674. PubMed ID: 33283949
[TBL] [Abstract][Full Text] [Related]
8. G9a - An Appealing Antineoplastic Target.
Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
10. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
11. H3K9 methyltransferase G9a and the related molecule GLP.
Shinkai Y; Tachibana M
Genes Dev; 2011 Apr; 25(8):781-8. PubMed ID: 21498567
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
